Safety Profile of Psilocybin for Cocaine Use Disorder

This early-Phase I interventional trial (n=10) aims to assess the safety profile of psilocybin (25mg) in individuals with cocaine use disorder (CUD).

The University of California, Los Angeles, is conducting this study to determine the cardiovascular and subjective effects of psilocybin in individuals with cocaine use disorder who wish to stop using cocaine.

Participants, aged 21 to 55, will receive a single oral dose of 25 mg psilocybin during a laboratory visit lasting from 9 am to 3 pm in a comfortable environment. Two clinicians will be present during the session, where participants will ingest the psilocybin capsule and then lie down on a couch to reflect on their experience. Changes in heart rate, blood pressure, and subjective effects will be measured at one-hour intervals post-ingestion. No blood draws, behavioural assessments, or neuroimaging are included.

Follow-up check-ins will occur remotely at 48 hours, and 10, 50, and 90 days post-session. The study is estimated to start in February 2024 and conclude by December 2024.

Topic Opioid Use Disorder Addiction
Compound Psilocybin
Country United States of America
Visit trial

Trial Details



Trial Number

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.